R&D ARTICLES

• How To Overcome Headwinds In Securing Funding For Rare Disease Research

  The current landscape is challenging to navigate, but the good news is that there are new and emerging business strategies and funding models to consider.

• How To Reap The Benefits Of Female Talent And Innovation

  Women bring different perspectives, experiences and questions to the table that can significantly impact the design and direction of research, such as ensuring more women and other underrepresented groups are enrolled in clinical trials.

• Tech-Heavy Drug Discovery Yields Deep Pipeline

  The Business of Biotech caught up with Recursion Co-Founder & CEO Chris Gibson, Ph.D. on the heels of the company launching four clinical trials in just three quarters. That progress was built on a foundation of rapid, machine-enabled drug discovery.

• How AI Is Driving Innovation And De-Risking R&D

  With AI there is real progress being made in determining, early on, with a greater degree of accuracy, which molecule might be a hit, and which one won’t.

• How Portage Biotech Created A Lean, New Drug Development Model

  Dr. Ian Walters noticed that Big Pharma companies often would lament that small biotechs did not develop drugs the same way as their larger counterparts. He set out to change that.

• How A Robust R&D Pipeline Can Safeguard Innovation

  By approaching R&D only as a means to a profitable product and not as a valuable asset for the broader scientific or consumer community, companies and the industry lose out on opportunities for innovation, collaboration, and discovery.

• Fueling A Focused Drug Development Model

  Privately held Debiopharm is laser-focused on oncology and infectious diseases, with a business model that strategically avoids drug discovery on one end, and commercialization on the other.

• What’s True Of Mice ≠ What’s True Of Men

  As ATMPs advance, scientists are calling out the limited value of mouse models in pharmacological research and testing. LIfT Biosciences’ Founder and CEO Alex Blyth is a vocal proponent of organoid/tumoroid models.

• Is AI/ML Bringing Medicines To Patients Faster And Cheaper?

  It is critical to move beyond simply using AI as a buzzword and instead determine if AL/ML does indeed change the discovery and clinical development process by bringing innovation to patients faster and at a lower investment.

• Building A Successful Internal Innovation Incubator

  With so many internal incubators failing, what is the right formula for success? Leading the U.S. Digital Transformation & Innovation team for Novo Nordisk, I was on the frontlines addressing this very question.